| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 38 |
| 1 | IPILIMUMAB | 22 |
| 2 | CARBOPLATIN | 8 |
| 3 | DURVALUMAB | 8 |
| 4 | FUROSEMIDE | 8 |
| 5 | AMLODIPINE | 7 |
| 6 | EPOPROSTENOL | 7 |
| 7 | MAGNESIUM OXIDE | 7 |
| 8 | SILDENAFIL CITRATE | 6 |
| 9 | ACETAMINOPHEN | 5 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | POTASSIUM IODIDE | 3 | 0.0020 |
| 1 | ALOGLIPTIN | 3 | 0.0009 |
| 2 | METRELEPTIN | 1 | 0.0008 |
| 3 | LEMBOREXANT | 2 | 0.0007 |
| 4 | SENNOSIDES A AND B | 1 | 0.0006 |
| 5 | NALDEMEDINE | 1 | 0.0006 |
| 6 | EPOPROSTENOL | 7 | 0.0005 |
| 7 | IPILIMUMAB | 22 | 0.0005 |
| 8 | DAPRODUSTAT | 1 | 0.0005 |
| 9 | CEMIPLIMAB-RWLC | 1 | 0.0005 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Leptin Analog [EPC] | 1 | 0.0008 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 22 | 0.0005 |
| 2 | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | 1 | 0.0004 |
| 3 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 38 | 0.0004 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 8 | 0.0004 |
| 5 | Orexin Receptor Antagonist [EPC] | 4 | 0.0002 |
| 6 | Chloride Channel Activator [EPC] | 2 | 0.0002 |
| 7 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 1 | 0.0002 |
| 8 | Soluble Guanylate Cyclase Stimulator [EPC] | 5 | 0.0001 |
| 9 | Thyroid Hormone Synthesis Inhibitor [EPC] | 1 | 0.0001 |